Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories australia pty ltd - ivabradine hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

servier laboratories nz ltd - strontium ranelate 2632mg - granules for oral suspension - 2 g - active: strontium ranelate 2632mg excipient: aspartame maltodextrin mannitol - treatment of severe (established) osteoporosis in postmenopausal women at high risk of fracture to reduce the risk of fracture.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - agomelatine, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; stearic acid; colloidal anhydrous silica; sodium starch glycollate type a; maize starch; lactose monohydrate; propylene glycol; butan-1-ol; ethanol; isopropyl alcohol; shellac; strong ammonia solution; indigo carmine aluminium lake; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; glycerol - treatment in adults of: - of major depression (mdd) including prevention of relapse - generalised anxiety disorder (gad)

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - lurasidone hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; pregelatinised maize starch; carnauba wax; magnesium stearate; mannitol; iron oxide yellow; indigo carmine; titanium dioxide; macrogol 6000 - latuda is indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - lurasidone hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: hypromellose; carnauba wax; magnesium stearate; mannitol; pregelatinised maize starch; croscarmellose sodium; titanium dioxide; macrogol 6000 - latuda is indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - amlodipine besilate, quantity: 13.87 mg; perindopril arginine, quantity: 10 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; lactose monohydrate; magnesium stearate - apx-perindopril arginine/ amlodipine is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 10 mg; amlodipine besilate, quantity: 6.935 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; colloidal anhydrous silica - apx-perindopril arginine/ amlodipine is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - amlodipine besilate, quantity: 13.87 mg; perindopril arginine, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; lactose monohydrate - apx-perindopril arginine/ amlodipine is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - amlodipine besilate, quantity: 6.935 mg; perindopril arginine, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; colloidal anhydrous silica - apx-perindopril arginine/ amlodipine is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; hydrophobic colloidal silica anhydrous; chlorophyllin-copper complex aluminium lake - indosyl mono is indicated for: the treatment of hypertension; indosyl mono is indicated for: the treatment of heart failure. in such patients it is recommended that indosyl mono be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of indosyl mono has not been demonstrated for new york heart association category iv patients) indosyl mono is indicated for: patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure to reduce the risk of non-fatal myocardial infarction or cardiac arrest.